Critical Update: AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma

Tamar H Taddei^{1

2}, Daniel B Brown³, Mark Yarchoan⁴, Mishal Mendiratta-Lala⁵, Josep M Llovet^{6

7

8}

Affiliations

¹ Department of Medicine (Digestive Diseases), Yale School of Medicine, New Haven, Connecticut, USA.
² Veterans Affairs Connecticut Healthcare System, West Haven, Connecticut, USA.
³ Department of Radiology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
⁴ Department of Medical Oncology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, USA.
⁵ Department of Radiology, University of Michigan Medical Center, Ann Arbor, Michigan, USA.
⁶ Liver Cancer Program, Division of Liver Diseases, Tisch Cancer Institute, Mount Sinai School of Medicine, New York, New York, USA.
⁷ Translational Research in Hepatic Oncology, Liver Unit, August Pi i Sunyer Biomedical Research Institute, Hospital Clinic, University of Barcelona, Catalonia, Spain.
⁸ Institució Catalana de Recerca i Estudis Avançats, Barcelona, Catalonia, Spain.

Tamar H Taddei et al. Hepatology. 2025.

. 2025 Jul 1;82(1):272-274.

doi: 10.1097/HEP.0000000000001269. Epub 2025 Feb 24.

Tamar H Taddei^{1

2}, Daniel B Brown³, Mark Yarchoan⁴, Mishal Mendiratta-Lala⁵, Josep M Llovet^{6

7

8}

¹ Department of Medicine (Digestive Diseases), Yale School of Medicine, New Haven, Connecticut, USA.
² Veterans Affairs Connecticut Healthcare System, West Haven, Connecticut, USA.
³ Department of Radiology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
⁴ Department of Medical Oncology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, USA.
⁵ Department of Radiology, University of Michigan Medical Center, Ann Arbor, Michigan, USA.
⁶ Liver Cancer Program, Division of Liver Diseases, Tisch Cancer Institute, Mount Sinai School of Medicine, New York, New York, USA.
⁷ Translational Research in Hepatic Oncology, Liver Unit, August Pi i Sunyer Biomedical Research Institute, Hospital Clinic, University of Barcelona, Catalonia, Spain.
⁸ Institució Catalana de Recerca i Estudis Avançats, Barcelona, Catalonia, Spain.

No abstract available

Keywords: adjuvant therapy; clinical trial; hepatocellular carcinoma; liver cancer; neoadjuvant therapy.

References

1. Singal AG, Llovet JM, Yarchoan M, Mehta N, Heimbach JK, Dawson LA, et al. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology. 2023;78:1922–1965.
1. Yopp A, Kudo M, Chen M, Cheng AL, Kaseb AO, Lee HC, et al. LBA39 updated efficacy and safety data from IMbrave050: Phase III study of adjuvant atezolizumab (atezo) + bevacizumab (bev) vs active surveillance in patients (pts) with resected or ablated high-risk hepatocellular carcinoma (HCC). Ann Oncol. 2024;35:S1230.
1. Roche’s Tecentriq plus Avastin is the first treatment combination to reduce the risk of cancer returning in people with certain types of early-stage liver cancer in a Phase III trial.
1. Singal AG, Rich NE, Mehta N, Branch AD, Pillai A, Hoteit M, et al. Direct-acting antiviral therapy for hepatitis C virus infection is associated with increased survival in patients with a history of hepatocellular carcinoma. Gastroenterology. 2019;157:1253–1263.e1252.
1. Cabibbo G, Celsa C, Calvaruso V, Petta S, Cacciola I, Cannavo MR, et al. Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients. J Hepatol. 2019;71:265–273.